Adaptive resistance: A tumor strategy to evade immune attack

Myeloid leukemia cells with a B7-2+subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands

(2012) Yusuf Dolen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

B7-H2 Is a Costimulatory Ligand for CD28 in Human

(2011) Sheng Yao et al.   IMMUNITY

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

(2010) Xiangli Chen et al.   CANCER BIOLOGY & THERAPY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

(2010) Elias A Said et al.   NATURE MEDICINE

PD-1 on dendritic cells impedes innate immunity against bacterial infection

(2009) S. Yao et al.   BLOOD